A comprehensive analysis of Lymphoma-associated haemophagocytic syndrome in a large French multicentre cohort detects some clues to improve prognosis

Lymphoma-associated haemophagocytic syndrome (LAHS) accounts for most cases of secondary haemophagocytic syndrome (HS) and has been extensively described in Asian populations. However, little is known about the epidemiology of LAHS in Western countries. We herein report a case series of 71 LAHS patients in which the lymphomas were mainly of the aggressive type. Diagnoses included non-Hodgkin B cell lymphoma (465%) including human herpes virus 8-associated non-Hodgkin lymphoma (127%), T cell lymphoma (282%) and Hodgkin lymphoma (239%). An underlying immunodeficiency was described in 30 patients (423%). Early mortality within the 30days following HS diagnosis was observed in 268% of cases. The overall survival was estimated at 457% [95% confidence interval, CI (354-590)] at 6months, and 343% [95% CI (248-474)] at 2years. Concurrent infection, age over 50years, ethnicity and etoposide treatment were independently associated with mortality. While it appears that certain types of lymphomas were more prone to trigger HS, LAHS were not restricted to a few types of lymphoma. The overall prognosis was poor, with a particularly high rate of early mortality, highlighting the importance of both early recognition and choice of initial therapeutic management.